In particular, loss of TIM-3 in DCs was recently associated with inflammasome activation and maintenance of CD8+ effector and stem-like T cells that supported anti-tumor immune responses, underscoring an important role for TIM-3 blockade in myeloid cells in the context of immunotherapies [16]. Here, HAVCR2 is linked to neoplasm.